Olympus Corporation
Olympus Corporation (OCPNF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ocpnf · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Olympus Corporation (OCPNF) measures how much investors pay for each dollar of the company's trailing earnings. OCPNF's current PE ratio of 28.97x is calculated by dividing its stock price of $11.18 by its TTM earnings per share of $61.66. +44.0% elevated vs 5Y avg 20.1x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 17 fiscal years · Front-end computedMinQ1 · 25%24.8x
MedianQ3 · 75%225.8x
Max
At 28.97x, OCPNF's current P/E is within its average historical range over the past 17 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Olympus CorporationYou OCPNF | $12.3B | 28.97x | -10.5% | $61.66 |
 Alibaba Health Information Technology Limited ALBBY | $7.3B | 29.76x | -8.0% | $2.33 |
 Alibaba Health Information Technology Limited ALBHF | $6.7B | 36.07x | +11.5% | $0.12 |
 bioMérieux S.A. BMXMF | $9.9B | 32.65x | +0.9% | $3.37 |
 CSPC Pharmaceutical Group Limited CHJTF | $12.0B | 22.34x | -31.0% | $0.33 |
 Eurofins Scientific SE ERFSF | $12.7B | 23.65x | -26.9% | $2.64 |
 Fisher & Paykel Healthcare Corporation Limited FSPKF | $13.2B | 49.69x | +53.5% | $0.81 |
Industry Average 6 peers with valid PE | — | 32.36x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | 24.00x | $61.70 | +19.9% | |
2025-03-31 FY2025 | 20.02x | $102.99 | +81.4% | |
2024-03-31 FY2024 | 11.04x | $199.91 | -45.2% | |
2023-03-31 FY2023 | 20.13x | $113.22 | -20.8% | |
2022-03-31 FY2022 | 25.42x | $90.22 | -88.7% | |
2021-03-31 FY2021 | 225.79x | $10.05 | +516.6% | |
2020-03-31 FY2020 | 36.62x | $46.18 | -82.0% | |
2019-03-31 FY2019 | 203.44x | $5.97 | +719.0% | |
2018-03-31 FY2018 | 24.84x | $41.71 | -20.3% | |
2017-03-31 FY2017 | 31.18x | $31.25 | +29.9% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Olympus Corporation (OCPNF) measures how much investors pay for each dollar of the company's trailing earnings. OCPNF's current PE ratio of 28.97x is calculated by dividing its stock price of $11.18 by its TTM earnings per share of $61.66.
Frequently asked questions
OCPNF pe ratio · 6 questionsOCPNF's current PE ratio is 28.97x as of 2026-06-09, based on a stock price of $11.18 and TTM EPS of $61.66. Data sourced from Financial Modeling Prep via OCPNF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Olympus Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09